86 related articles for article (PubMed ID: 15520142)
1. Comments on the Prosser et Al approach to value disease reduction in children.
Beutels P; Viney RC
Pediatrics; 2004 Nov; 114(5):1375; author reply 1375-6. PubMed ID: 15520142
[No Abstract] [Full Text] [Related]
2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
3. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
[TBL] [Abstract][Full Text] [Related]
4. Nurse-supported breastfeeding promotion: a framework for economic evaluation.
Frick KD; Milligan RA; White KM; Serwint JR; Pugh LC
Nurs Econ; 2005; 23(4):165-72, 206, 147. PubMed ID: 16189981
[TBL] [Abstract][Full Text] [Related]
5. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
[TBL] [Abstract][Full Text] [Related]
6. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
7. Toward a consensus on the QALY.
Drummond M; Brixner D; Gold M; Kind P; McGuire A; Nord E;
Value Health; 2009 Mar; 12 Suppl 1():S31-5. PubMed ID: 19250129
[No Abstract] [Full Text] [Related]
8. Money matters: what to look for in an economic analysis.
Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
[No Abstract] [Full Text] [Related]
9. Patient preferences and cost-utility analysis.
Elnitsky CA; Stone P
Appl Nurs Res; 2005 May; 18(2):74-6. PubMed ID: 15991103
[TBL] [Abstract][Full Text] [Related]
10. What affects the quality of economic analysis for life-saving investments?
Hahn RW; Kosec K; Neumann PJ; Wallsten S
Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
[TBL] [Abstract][Full Text] [Related]
11. Costs associated with ventricular assist device use in children.
Mahle WT; Ianucci G; Vincent RN; Kanter KR
Ann Thorac Surg; 2008 Nov; 86(5):1592-7. PubMed ID: 19049755
[TBL] [Abstract][Full Text] [Related]
12. Quality-adjusted life years.
Bravo Vergel Y; Sculpher M
Pract Neurol; 2008 Jun; 8(3):175-82. PubMed ID: 18502950
[TBL] [Abstract][Full Text] [Related]
13. Valuing reduced antibiotic use for pediatric acute otitis media.
Meropol SB
Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
[TBL] [Abstract][Full Text] [Related]
14. The use of quality-adjusted life-years in cost-effectiveness studies.
Sculpher M
Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
[No Abstract] [Full Text] [Related]
15. Value-based medicine.
Kymes SM; Vollman D; Frick KD
Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
[No Abstract] [Full Text] [Related]
16. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
17. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
[TBL] [Abstract][Full Text] [Related]
18. On the lottery equivalents method: a response to Spencer et al.
Oliver A
Health Econ; 2006 Mar; 15(3):323-5. PubMed ID: 16432804
[No Abstract] [Full Text] [Related]
19. Budget impact analysis and its rational basis.
Hilden J
Med Decis Making; 2008; 28(4):460-1. PubMed ID: 18660488
[No Abstract] [Full Text] [Related]
20. [The cost per year of life gained: trends and internal contradictions].
van Dam J
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):441; author reply 441-2. PubMed ID: 17343145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
